pharma · Extensive-stage Small Cell Lung Cancer · Gastric Cancer
Fudan University
Shanghai Medical College drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Medical College drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Development asset linked to Shanghai Medical College in public FDA and regional records. Molecular target: Platelet-derived growth factor receptor beta.
Development asset linked to Shanghai Medical College in public FDA and regional records.
Development asset linked to Shanghai Medical College in public FDA and regional records.